Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Skye Bioscience Inc
(OP:
SKYE
)
N/A
UNCHANGED
Last Price
Updated: 3:57 PM EDT, Apr 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Skye Bioscience Inc
< Previous
1
2
3
Next >
Skye Bioscience Announces $40 Million Private Placement Equity Financing
March 11, 2024
San Diego, California--(Newsfile Corp. - March 11, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) (the Company), a clinical stage biotechnology...
Via
Newsfile
Skye Bioscience to Present at Oppenheimer Investor Conference
February 07, 2024
San Diego, California--(Newsfile Corp. - February 7, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a clinical-stage biotechnology company focused...
Via
Newsfile
Skye Bioscience And 2 Other Penny Stocks Insiders Are Buying
February 05, 2024
The Dow Jones index closed higher by more than 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
January 29, 2024
San Diego, California--(Newsfile Corp. - January 29, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("the Company"), a clinical stage biotechnology...
Via
Newsfile
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
January 09, 2024
San Francisco, California--(Newsfile Corp. - January 9, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa
December 05, 2023
San Diego, California and Johannesburg, South Africa--(Newsfile Corp. - December 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a...
Via
Newsfile
Topics
Cannabis
Intellectual Property
Exposures
Cannabis
Intellectual Property
Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit
November 21, 2023
San Diego, California--(Newsfile Corp. - November 21, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs...
Via
Newsfile
Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma
October 25, 2023
• SBI-100 OE is well tolerated, with low rate of hyperaemia...
Via
Newsfile
CORRECTION: Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"
October 20, 2023
This document replaces and updates the previous version with the current OTCQB ticker for Skye Bioscience, Inc.San Diego, California--(Newsfile Corp....
Via
Newsfile
Skye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
San Diego, California--(Newsfile Corp. - September 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing proprietary...
Via
Newsfile
Marijuana Stock Movers For August 23, 2023
August 23, 2023
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Cannabis Stock Gainers And Losers From August 25, 2023
August 25, 2023
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Skye Secures $17M And Acquires Novel Phase 2-Ready Cannabinoid 1 Receptor Inhibitor
August 21, 2023
Skye Bioscience, Inc. (OTCQB: SKYE) has undertaken a strategic initiative that expands the company's resources and technologies focused on developing therapeutic products focused on the endocannabinoid...
Via
Benzinga
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
August 21, 2023
New capital funds anticipated Phase 2a glaucoma clinical trial Nimacimab is a first-in-class peripherally-restricted negative allosteric modulator antibody inhibitor of...
Via
Newsfile
Cannabis Stock Gainers And Losers From August 24, 2023
August 24, 2023
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Cannabis Stock Movers For August 18, 2023
August 18, 2023
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Marijuana Stock Movers For August 22, 2023
August 22, 2023
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Skye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
August 14, 2023
San Diego, California--(Newsfile Corp. - August 14, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing a...
Via
Newsfile
Bearish Monday For Marijuana Stocks - EVIO, Item 9 Labs Among Top Gainers
August 07, 2023
Via
Benzinga
Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023
August 21, 2023
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Bullish Thursday For Marijuana Stocks - EVIO, Tetra Bio Pharma Among Top Gainers
August 17, 2023
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Cannabis Stock Gainers And Losers From August 16, 2023
August 16, 2023
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Cannabis Stock Gainers And Losers From August 14, 2023
August 14, 2023
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Cannabis Stock Gainers And Losers From August 11, 2023
August 11, 2023
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Marijuana Stock Movers For August 8, 2023
August 08, 2023
Via
Benzinga
Marijuana Stock Movers For August 2, 2023
August 02, 2023
Via
Benzinga
Marijuana Stock Movers For August 1, 2023
August 01, 2023
Via
Benzinga
Marijuana Stock Movers For July 31, 2023
July 31, 2023
Via
Benzinga
Cannabis Stock Gainers And Losers From July 28, 2023
July 28, 2023
Via
Benzinga
Cannabis Stock Gainers And Losers From July 26, 2023
July 26, 2023
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.